Lactones

• 

  Subject Areas on Research

  • A formal synthesis of SCH 351448. 
  • A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss. 
  • Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors. 
  • Anti-AIDS agents 86. Synthesis and anti-HIV evaluation of 2',3'-seco-3'-nor DCP and DCK analogues. 
  • Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? 
  • Antitumor Agents, CLI. Bis(helenalinyl)Glutarate and Bis(isoalantodiol-B)-Glutarate, Potent Inhibitors of Human DNA Topoisomerase II 
  • Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. 
  • Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). 
  • Balancing the cyclooxygenase portfolio. 
  • Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. 
  • Camptothecin analogues with enhanced antitumor activity at acidic pH. 
  • Cerivastatin Nanoliposome as a Potential Disease Modifying Approach for the Treatment of Pulmonary Arterial Hypertension. 
  • Compatibility and stability of bryostatin 1 in infusion devices. 
  • Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice. 
  • Depside and Depsidone Synthesis in Lichenized Fungi Comes into Focus through a Genome-Wide Comparison of the Olivetoric Acid and Physodic Acid Chemotypes of Pseudevernia furfuracea. 
  • Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. 
  • Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. 
  • Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. 
  • Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy. 
  • Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. 
  • Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. 
  • Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs. 
  • Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death. 
  • Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). 
  • Health agencies end in-fighting on malaria. 
  • How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior. 
  • Inhibition of radiation-induced up-regulation of leukocyte adhesion to endothelial cells with the platelet-activating factor inhibitor, BN52021. 
  • Insights from the first putative biosynthetic gene cluster for a lichen depside and depsidone. 
  • Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. 
  • Letter: Polyene antibiotics. VI. The structures of dermostatins A and B. 
  • Ligand interactions in the adenosine nucleotide-binding domain of the Hsp90 chaperone, GRP94. II. Ligand-mediated activation of GRP94 molecular chaperone and peptide binding activity. 
  • Light might regulate divergently depside and depsidone accumulation in the lichen Parmotrema hypotropum by affecting thallus temperature and water potential. 
  • Low HDL predicts differential blood pressure effects from two weight-loss approaches: a secondary analysis of blood pressure from a randomized, clinical weight-loss trial. 
  • Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. 
  • Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives. 
  • Modulation of the combinatorial code of odorant receptor response patterns in odorant mixtures. 
  • N-Heterocyclic carbene catalyzed oxidative macrolactonization: total synthesis of (+)-dactylolide. 
  • Nonsteroidal anti-inflammatory drugs and acetaminophen in the treatment of an acute muscle injury. 
  • PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis. 
  • Patient detection of a drug dispensing error by use of physician-provided drug samples. 
  • Periodic root branching in Arabidopsis requires synthesis of an uncharacterized carotenoid derivative. 
  • Poly(lactide-co-ε-caprolactone) scaffold promotes equivalent tissue integration and supports skin grafts compared to a predicate collagen scaffold. 
  • Polyene antibiotics. IV. Structure of chainin. 
  • Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome. 
  • Pyruvate aldolases in chiral carbon-carbon bond formation. 
  • Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. 
  • Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. 
  • Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. 
  • Role of platelet activating factor in kidney transplant rejection in the rat. 
  • Role of platelet activating factor in the intestinal epithelial secretory and Chinese hamster ovary cell cytoskeletal responses to cholera toxin. 
  • Role of platelet-activating factor in Chinese hamster ovary cell responses to cholera toxin. 
  • Role of prostacyclin in the cardiovascular response to thromboxane A2. 
  • Role of transmethylation reactions in cellular motility and phagocytosis. 
  • S-adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin. 
  • Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. 
  • Stereoselective synthesis of 2,6-cis-tetrahydropyrans through a tandem allylic oxidation/oxa-Michael reaction promoted by the gem-disubstituent effect: synthesis of (+)-neopeltolide macrolactone. 
  • Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. 
  • Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation. 
  • Structure-property relationships in 3D-printed poly(l-lactide-co-ε-caprolactone) degradable polymer. 
  • Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx). 
  • The clinical treatment of childhood obesity. 
  • The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. 
  • The relationship between pretreatment dietary composition and weight loss during a randomised trial of different diet approaches. 
  • Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. 
  • Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. 
  • Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. 
  • Use of bacterial quorum-sensing components to regulate gene expression in plants. 
  • Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. 
  • Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). 
  • Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. 
  • Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). 
  • Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). 
  • Vorapaxar in the secondary prevention of atherothrombosis. 
  • Vorapaxar in the secondary prevention of atherothrombotic events. 
  • Vorapaxar in the treatment of cardiovascular diseases. 
  • Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. 
  • Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. 
  • Vorapaxar: a novel protease-activated receptor-1 inhibitor. 
  • What about celebrex? 
• 

  Keywords of People

  • Grambow, Steven C., Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • Olsen, Maren Karine, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics